Clinical Trial Update: MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) [Phase 1]

View source ↗

Summary

Phase 1 single-dose study of MK-8583 in HIV-1 infected participants completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MK-8583 (MK-8583)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 1 | Status: COMPLETED | Results posted: 2020-03-04